Andreas D. Orskov

Roskilde, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Bone marrow immunosuppressive states associate with survival after guadecitabine and atezolizumab therapy in HMA-R/R MDS.

Bone marrow immunosuppressive states associate with survival after guadecitabine and atezolizumab therapy in HMA-R/R MDS.

Journal: Blood neoplasia

Published: January 29, 2026

A Danish nationwide population-based cohort study on acute myeloid leukemia with RUNX1::RUNX1T1 - Real-world outcomes and clinicopathological characteristics.

A Danish nationwide population-based cohort study on acute myeloid leukemia with RUNX1::RUNX1T1 - Real-world outcomes and clinicopathological characteristics.

Journal: Blood cancer journal

Published: June 23, 2025

Cardiotoxicity in patients with acute myeloid leukaemia following anthracycline-containing chemotherapy: A population-based matched cohort study.

Cardiotoxicity in patients with acute myeloid leukaemia following anthracycline-containing chemotherapy: A population-based matched cohort study.

Journal: British journal of haematology

Published: April 29, 2025

Reproductive patterns and birth rates in acute leukaemia survivors: A Danish population-based cohort study.

Reproductive patterns and birth rates in acute leukaemia survivors: A Danish population-based cohort study.

Journal: British journal of haematology

Published: March 14, 2025

Outcomes and prognostic impact of trisomy 8 in acute myeloid leukemia patients treated with intensive chemotherapy.

Outcomes and prognostic impact of trisomy 8 in acute myeloid leukemia patients treated with intensive chemotherapy.

Journal: Blood cancer journal

Published: February 17, 2025

Bone marrow microenvironment signatures associate with patient survival after guadecitabine and atezolizumab therapy in HMA-resistant MDS.

Bone marrow microenvironment signatures associate with patient survival after guadecitabine and atezolizumab therapy in HMA-resistant MDS.

Journal: bioRxiv : the preprint server for biology

Published: November 28, 2024

Second primary non-myeloid malignancies following intensive treatment for adult acute myeloid leukaemia: a Danish population-based cohort study.

Second primary non-myeloid malignancies following intensive treatment for adult acute myeloid leukaemia: a Danish population-based cohort study.

Journal: The Lancet regional health. Europe

Published: October 16, 2024

Outcomes among non-Western immigrant patients and Danish-born patients with acute myeloid Leukaemia: A Danish population-based cohort study.

Outcomes among non-Western immigrant patients and Danish-born patients with acute myeloid Leukaemia: A Danish population-based cohort study.

Journal: British journal of haematology

Published: September 02, 2024

Temporal changes in survival among adult patients with acute lymphoblastic leukaemia diagnosed in the period 1998-2020 - A Danish nationwide population-based cohort study.

Temporal changes in survival among adult patients with acute lymphoblastic leukaemia diagnosed in the period 1998-2020 - A Danish nationwide population-based cohort study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 13, 2024

Overlapping DNA methylation changes in enhancers in clonal cytopenia of undetermined significance and myelodysplastic neoplasm patients with TET2, IDH2, or DNMT3A mutations.

Overlapping DNA methylation changes in enhancers in clonal cytopenia of undetermined significance and myelodysplastic neoplasm patients with TET2, IDH2, or DNMT3A mutations.

Journal: Haematologica

Published: April 04, 2024

Work Disability and Return to Work After Treatment for Acute Lymphoblastic Leukemia: A Danish Nationwide Cohort Study.

Work Disability and Return to Work After Treatment for Acute Lymphoblastic Leukemia: A Danish Nationwide Cohort Study.

Journal: Clinical epidemiology

Published: October 11, 2023

Venetoclax-based therapy for relapsed or refractory acute myeloid leukaemia following intensive induction chemotherapy.

Venetoclax-based therapy for relapsed or refractory acute myeloid leukaemia following intensive induction chemotherapy.

Journal: European journal of haematology

Published: June 06, 2023

Showing 1-12 of 26

Last Updated: 09/26/2026